Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
181
-
Total 13F shares, excl. options
-
70.3M
-
Shares change
-
+1.49M
-
Total reported value, excl. options
-
$1.14B
-
Value change
-
+$20.8M
-
Put/Call ratio
-
0.84
-
Number of buys
-
96
-
Number of sells
-
-86
-
Price
-
$16.22
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q1 2020
218 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q1 2020.
Coherus Oncology, Inc. - Common Stock (CHRS) has 181 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 70.3M shares
of 115M outstanding shares and own 60.95% of the company stock.
Largest 10 shareholders include Temasek Holdings (Private) Ltd (7.38M shares), BlackRock Inc. (5.45M shares), STATE STREET CORP (3.5M shares), AMERIPRISE FINANCIAL INC (3.44M shares), ALLIANCEBERNSTEIN L.P. (3.23M shares), VANGUARD GROUP INC (3.13M shares), Kohlberg Kravis Roberts & Co. L.P. (3.04M shares), WELLINGTON MANAGEMENT GROUP LLP (2.31M shares), Consonance Capital Management LP (2.02M shares), and Rock Springs Capital Management LP (1.95M shares).
This table shows the top 181 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.